Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Electrochemiluminescence platform for the detection of C-reactive proteins : application of recombinant antibody technology to cardiac biomarker detection

O'Reilly, Emmet J. and Conroy, Paul J. and Hearty, Stephen and Keyes, Tia E. and O'Kennedy, Richard and Forster, Robert J. and Dennany, Lynn (2015) Electrochemiluminescence platform for the detection of C-reactive proteins : application of recombinant antibody technology to cardiac biomarker detection. RSC Advances, 5 (83). pp. 67874-67877. ISSN 2046-2069

[img]
Preview
Text (O'Reilly-etal-RSCA2015-Electrochemiluminescence-platform-for-the-detection-of-C-reactive-proteins)
O_Reilly_etal_RSCA2015_Electrochemiluminescence_platform_for_the_detection_of_C_reactive_proteins.pdf
Accepted Author Manuscript

Download (661kB) | Preview

Abstract

This work exploits the high-affinity of recombinant antibodies and low background electrochemiluminescence (ECL) for cardiac-biomarker detection. The developed assay is capable of fg mL-1 detection limits as well as the detection of C-Reactive Protein (CRP) over a clinically relevant range. The assay demonstrated robust reproducibility, selectivity and stability while also highlighting a novel platform for detection of cardiac biomarkers at low concentrations.